^
Association details:
| Biomarker: | POLE mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Jemperli (dostarlimab-gxly) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
Excerpt:
...- POLE-mutated endometrial cancers will be included...
Trial ID:
Source:
Title:
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial
Published date:
11/01/2023
Excerpt:
Participants had advanced or recurrent dMMR and microsatellite instability-high (MSI-H) or polymerase epsilon (POLE)-altered solid tumors...The ORR for patients with POLE-altered solid tumors was 54.5% (6 of 11; 95% CI, 23.4%-83.3%).
DOI:
10.1001/jamanetworkopen.2023.41165
Trial ID:
Source:
Title:
Efficacy and safety of dostarlimab in UK-specific patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) or DNA polymerase epsilon, catalytic subunit (POLƐ)-mutated solid tumours in the GARNET study
Published date:
06/27/2023
Excerpt:
Median PFS was 5.4 months (3-year rate, 39.7%) and median OS was 18 months (3-year rate, 47.3%) in patients overall....Dostarlimab demonstrated durable, clinically meaningful anti-tumour activity in UK-specific patients with dMMR/MSI-H or POLƐ-mutated solid tumours...
Trial ID:
Source:
Title:
SO-9 Analysis of the immune-related endpoints of the mismatch repair–deficient non-endometrial solid cancers cohort from the GARNET study
Published date:
07/04/2021
Excerpt:
...3 patients with POLε-m solid tumors...Confirmed irORR was observed in 50 (45.5%) dMMR patients, which included 2 patients with POLε-m...Dostarlimab demonstrated durable antitumor activity by irRECIST per IA across multiple tumor types.
DOI:
10.1016/j.annonc.2021.05.033
Trial ID:
